Rotate your device

Please rotate your device to landscape mode
for the best experience.

AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Pirfetab 267 Tablet

Prescription Icon
Prescription Required

Marketer

Zydus Cadila

Salt Composition

Pirfenidone (267mg)

Overview Pirfetab 267 Tablet

Nintedanib (Pirfetab 267 mg) is a prescription medication indicated for idiopathic pulmonary fibrosis. It lessens lung inflammation and fibrosis, improving breathing capacity. Optimal absorption occurs when taken with food, consistently at the same time daily for maximum therapeutic effect. Dosage frequency varies depending on individual needs and will be determined by your physician to manage your symptoms effectively. Continue taking this medication as prescribed. Common adverse effects include sleep disturbances, headache, vertigo, indigestion, nausea, diarrhea, and photosensitivity. To minimize dizziness, refrain from driving or activities requiring focus. Weight loss is also possible; regular monitoring or consultation with your doctor is advisable. Liver function tests may be conducted during treatment. Prior to initiating therapy, disclose any existing liver or kidney conditions, as well as all other medications you are currently using, to your physician, as interactions may affect efficacy. Due to increased sun sensitivity, protective clothing and sunscreen are recommended during sun exposure. Notify your doctor if you are pregnant or nursing.

Uses of Pirfetab 267 Tablet

Managing idiopathic pulmonary fibrosis

Major Benefits of Pirfetab 267 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Pirfetab 267 Tablet whole; avoid chewing, crushing, or breaking it. Administer this medicine with a meal.

Common Side effects of Pirfetab 267 Tablet:

  • Insomnia (difficulty in sleeping)
  • Headache
  • Dizziness
  • Tiredness
  • Sinus inflammation
  • Loss of appetite
  • Upper respiratory tract infection
  • Weight loss
  • Nausea
  • Indigestion
  • Diarrhea
  • Photosensitivity

How to use Pirfetab 267 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for Pirfetab 267 Tablets. Ingest the tablets whole; do not crush, chew, or divide them. Always take this medication with food.

How Pirfetab 267 Tablet works:

Pirfenidone 267mg tablets are an antifibrotic agent. Their mechanism of action involves inhibiting a specific endogenous molecule contributing to fibrosis development. This consequently lessens pulmonary scarring and inflammation, improving respiratory function.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

Alcohol consumption alongside Pirfetab 267 Tablet may pose unknown risks. Seek medical advice before combining them.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Pirfetab 267 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Data on Pirfetab 267 Tablet use while breastfeeding is lacking. Seek your physician's advice.

DrivingDrivingUNSAFE

Taking Pirfetab 267 Tablets might reduce awareness, impair vision, and cause drowsiness or dizziness. Refrain from driving if you experience these effects.

KidneyKidneyCAUTION

Patients with kidney impairment should use Pirfetab 267 Tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. Pirfetab 267 Tablets are contraindicated for individuals with severe kidney disease or those undergoing dialysis.

LiverLiverCAUTION

Individuals with liver impairment should use Pirfetab 267 Tablets cautiously, potentially requiring dosage modification. Medical advice is essential. Pirfetab 267 Tablets are contraindicated in patients exhibiting severe hepatic dysfunction.

What if you forget to take Pirfetab 267 Tablet :

NA

Facts to Know About Pirfetab 267 Tablet

LabelValue
Chemical Type Pyridone Derivative
Developing Habits No.
Treatment Category Breathing
Actions Pulmonary fibrosis of unknown cause

FAQs on Pirfetab 267 Tablet

Prior to beginning Pirfetab 267 Tablet treatment, your doctor will assess your liver function. This assessment will recur monthly for six months, then quarterly thereafter. Your lung function will also be monitored regularly to evaluate your response to the medication.
Protecting your irreplaceable lung function is crucial for managing this disease. Therefore, consistently taking Pirfetab 267 Tablet as directed by your doctor is strongly recommended to help maintain your current lung capacity.
Pirfetab 267 Tablet may cause sun sensitivity, nausea, fatigue, diarrhea, indigestion, appetite loss, and headache. Other possible side effects include upper respiratory and bladder infections, weight loss, sleep disturbances (insomnia or drowsiness), altered taste, hot flashes, shortness of breath, cough, and acid reflux. Further potential side effects are vomiting, bloating, abdominal pain, heartburn, constipation, itchy, red, dry, or rashy skin, muscle and joint pain, weakness, chest pain, sunburn, and elevated liver enzymes (detected via blood tests).
Pirfetab 267 tablets are not steroids; they're pyridines used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF causes lung tissue scarring and swelling, impairing breathing. This medication helps alleviate these effects, improving respiratory function.
You and your doctor should determine if Pirfetab 267 Tablet is appropriate for you. Your doctor will prescribe it only after evaluating your health. Continued use depends on your response to treatment and how well you tolerate the medication.
Idiopathic pulmonary fibrosis progresses unpredictably. Discontinue Pirfetab 267 Tablet only after consulting your doctor. Continued use may help slow disease progression.
Minimize sun exposure while taking Pirfetab 267 Tablet. Use sunscreen daily and protect your skin by covering exposed areas. Additionally, refrain from smoking to maximize the medication's effectiveness.
While the average lifespan for pulmonary fibrosis patients is two to three years, some individuals survive significantly longer. Reduced survival is associated with older age, smoking, and lower BMI. Further contributing factors include advanced disease severity (radiologically and functionally) and the onset of additional lung problems.
Pirfetab 267 Tablet
261
MRP 303
13% off